At a clinical level, previous studies have shown that LKB1 expression is associated with improved survival in patients with advanced non-small cell lung cancer receiving chemotherapy and bevacizumab treatment [64], while the loss of tumoral LKB1 expression serves as a negative prognostic indicator in patients with operable colorectal cancer [65]. Here, STK11 is linked to non-small cell lung carcinoma.